Cramer Rosenthal McGlynn’s LeMaitre Vascular LMAT Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-249,029	Closed	-$20.5M	–	99
2024 Q2	$20.5M	Sell	249,029 -21,215	-8%	-$1.56M	1.2%	37
2024 Q1	$17.9M	Sell	270,244 -76,886	-22%	-$4.74M	0.97%	48
2023 Q4	$19.7M	Buy	347,130 +189,839	+121%	+$9.94M	1.07%	42
2023 Q3	$8.57M	Buy	157,291 +2,453	+2%	+$145K	0.48%	76
2023 Q2	$10.4M	Sell	154,838 -221,199	-59%	-$13.5M	0.52%	68
2023 Q1	$19.4M	Sell	376,037 -87,595	-19%	-$4.25M	0.87%	47
2022 Q4	$21.3M	Buy	463,632 +23,298	+5%	+$1.09M	0.94%	44
2022 Q3	$22.3M	Sell	440,334 -21,069	-5%	-$1.05M	1.07%	39
2022 Q2	$21M	Buy	+461,403	New	+$20.6M	0.97%	43

Other funds holding LMAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cramer Rosenthal McGlynn's LMAT Position: Q3 2024 in Review

Cramer Rosenthal McGlynn sold out of LeMaitre Vascular (LMAT) in Q3 2024, closing a stake of 249,029 shares — an estimated $20.5M sold.

Cramer Rosenthal McGlynn first reported a position in LMAT in Q2 2022 and held it in 9 quarters. The position peaked at $22.3M in Q3 2022. 291 funds tracked by Wall St. Rank hold LMAT as of Q3 2024.

Cramer Rosenthal McGlynn reported no remaining LeMaitre Vascular position as of Q3 2024 after selling out during the quarter.
Cramer Rosenthal McGlynn sold 249,029 LeMaitre Vascular shares in Q3 2024, an estimated $20.5M.
Cramer Rosenthal McGlynn first reported a position in LeMaitre Vascular in Q2 2022 and held it in 9 quarters.
Cramer Rosenthal McGlynn's LeMaitre Vascular position peaked at $22.3M in Q3 2022.
291 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q3 2024.

Based on Cramer Rosenthal McGlynn's 13F filing for Q3 2024, filed 14 Nov 2024.